Arterial Thrombosis in Patients with Cancer
Purpose of review
Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients.
Based on a recent study looking at the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of arterial thromboembolic events (ATEs) in patients with cancer at 6 months is 4.7%; the presence of an ATE is predictive of worse outcomes. Certain drugs such as platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, and taxanes have been associated with high rates of ATEs. Increased platelet reactivity appears crucial to development of arterial thrombosis in cancer patients.
Cancer patients have an increased risk of arterial thrombosis that is likely due to both a cancer-associated procoagulant state as well as the adverse effects of certain chemotherapeutic agents. Treatment of arterial thromboembolism in cancer patients typically requires a multidisciplinary approach in part due to high rates of thrombocytopenia and stent thrombosis in the setting of percutaneous interventions. More studies are needed to investigate optimal prophylaxis, surveillance strategies, and treatments of cancer-related arterial thromboembolic disease.
KeywordsArterial thrombosis Cancer Chemotherapy
Compliance with Ethical Standards
Conflict of Interest
Mirela Tuzovic, Cezar Iliescu, Kostas Marmagkiolis, Boback Ziaeian, and Eric H. Yang each declare no potential conflicts of interest.
Joerg Herrmann was a participant in the 2014 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals and the 2015 Advisory Board meeting of the Institute for Cardio-Oncology sponsored by Bristol-Myers Squibb.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Prevention C for DC and. Deaths and mortality. 2017. Available at: https://www.cdc.gov/nchs/fastats/deaths.htm. Accessed October 12, 2017.
- 2.Institute NC. Cancer statistics. Available at: https://www.cancer.gov/about-cancer/understanding/statistics. Accessed January 1, 2017.
- 3.American Cancer Society, Cancer Treatment & Survivorship: Facts &Figures, 2016-2017. https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-factsand-figures/cancer-treatment-and-survivorship-facts-and-figures-2016-2017.pdf. Accessed 16 Mar 2018.
- 5.Blann AD DS. Arterial and venous thrombosis in cancer patients. Cardiol Res Pr 2011:394740.Google Scholar
- 8.•• Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–38. The authors describe the incidence of arterial thromboembolic events in cancer patients included in the SEER database. Incidence with respect to time from diagnosis, the type of cancer, and the cancer stage is also reportedCrossRefPubMedGoogle Scholar
- 9.Abbott JD, Ahmed HN, Vlachos HA, Selzer FWD. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute dynamic registry). Am J Cardiol. 2007;100:190–5.CrossRefPubMedGoogle Scholar
- 10.Wang F, Gulati R, Lennon RJ, Lewis BR, Park J, Sandhu GS, et al. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc. 2016;91:1680–92.CrossRefPubMedGoogle Scholar
- 16.Sugrue, MM, Yi, J, Purdie, D, Dong, W, Grothey, A, Kozloff M. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry. J Clin Oncol.Google Scholar
- 23.Plana JC, Chair MG, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.CrossRefPubMedGoogle Scholar
- 26.FDA. Ponatinib. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203469s009lbl.pdf.
- 55.Gov.uk, Drug Safety Update. Lenalidomide: risk of thrombosis and thromboembolism. https://www.gov.uk/drug-safety-update/lenalidomide-risk-ofthrombosis-and-thromboembolism. Accessed 16 Mar 2018.
- 56.Rumbaut RE, Thiagarajan P. Platelet-vessel wall interactions inHemostasis and thrombosis. Chapter 6: arterial, venous, and microvascular hemostasis/thrombosis. San Rafael: Morgan & Claypool Life Sciences; 2010 https://www.ncbi.nlm.nih.gov/books/NBK53450. Accessed 16 Mar 2018.
- 66.• Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and sociedad Latino Americana de Cardiologıa interve). Catheter Cardiovasc Interv. 2016;87:E202–23. This article describes the current expert consensus regarding management of cancer patients requiring evaluation in the catheterization laboratory. Cancer associated complications such as thrombocytopenia require special attention when treating arterial thromboembolic diseaseCrossRefPubMedGoogle Scholar
- 77.Gremmel T, Perkmann T, Seidinger D, Koppensteiner R, Panzer S, Kopp CWSS. Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. J Atheroscler Thromb. 2013;20:630–45.CrossRefPubMedGoogle Scholar
- 80.Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012;7:119(23):5543–52. https://doi.org/10.1182/blood-2012-01-402156.
- 86.Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman HDW, infarction and the WG on behalf of the JETF for the UD of M. Third universal definition of myocardial infarction. Circulation 2012;126:2020–2035.Google Scholar
- 88.Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS). Am Heart J. 2011;161:391–6.CrossRefPubMedGoogle Scholar
- 92.Douglas G, Van Kampen E, Hale AB, McNeill E, Patel J, Crabtree MJ, et al. Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Eur Heart J. 2013;34:3378–88.CrossRefPubMedGoogle Scholar
- 97.Cooke NM, Spillane CD, Sheils O, O’Leary JKD. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BMC Cancer. 2015;627Google Scholar
- 106.A phase 2 pilot study of apixaban for the prevention of thromboembolic events in patients with advanced (metastatic) cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT00320255. Last Accessed February 10, 2018.
- 107.Biomarkers related to thrombosis in patients with newly diagnosed multiple myeloma receiving chemotherapy. Available at: https://clinicaltrials.gov/ct2/show/NCT01132833. Last Accessed February 10, 2018.
- 108.Anti-platelet and statin therapy to prevent cancer-associated thrombosis. https://clinicaltrials.gov/ct2/show/NCT02285738. Last Accessed February 10, 2018.
- 109.Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://clinicaltrials.gov/ct2/show/NCT02048865. Last Accessed February 10, 2018.
- 110.Enoxaparin Versus Aspirin in Patients with Cancer and Stroke. https://clinicaltrials.gov/ct2/show/NCT01763606. Accessed 16 Mar 2018.